Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
itching
Biotech
Attovia's CEO aims to scratch itch opportunity with $289M IPO
Attovia plans to use the IPO haul to kick off two large ph. 2 studies for ATTO-1310, a biologic that blocks the itch-inducing interleukin-31.
Darren Incorvaia
Aug 5, 2026 7:00am
Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent
Jul 15, 2026 4:09am
Ipsen scuttles liver disease candidates from Albireo acquisition
May 6, 2026 3:10pm
Mirum maps FDA path after anti-itch candidate scores ph. 2 win
May 4, 2026 10:40am
Alfasigma's $690M deal for GSK itch drug awaiting FDA decision
Mar 9, 2026 6:55am
GSK posts phase 3 itch data as it closes in on FDA approval
May 8, 2025 8:50am
